Clinical Trials Directory

Trials / Completed

CompletedNCT03772756

EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
38 (actual)
Sponsor
First People's Hospital of Hangzhou · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Accepted

Summary

the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.

Detailed description

The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis .

Conditions

Interventions

TypeNameDescription
PROCEDUREEndoscopic ultrasound guided radiofrequency ablationEndoscopic ultrasound guided radiofrequency ablation (EUS-RFA) will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
RADIATIONchemoradiotherapyReceive chemoradiotherapy

Timeline

Start date
2018-12-20
Primary completion
2021-08-16
Completion
2021-08-16
First posted
2018-12-11
Last updated
2021-08-30

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT03772756. Inclusion in this directory is not an endorsement.